Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00PMB
|
|||
| Former ID |
DNCL002612
|
|||
| Drug Name |
VGX-3100
|
|||
| Indication | Cervical Intraepithelial neoplasia [ICD-11: 2E66.1; ICD-10: N87.2] | Phase 3 | [1] | |
| Dysplasia [ICD-11: LB30-LD2F; ICD-10: C92.A2] | Phase 3 | [2] | ||
| Human papillomavirus infection [ICD-11: 1A9Y] | Phase 2 | [3] | ||
| Vulvar intraepithelial neoplasia [ICD-11: 2E67.10; ICD-10: N90.1, N90.2] | Phase 2 | [2] | ||
| Vulvar squamous intraepithelial lesion [ICD-11: 2E66.1; ICD-10: N87.2] | Phase 2 | [1] | ||
| Company |
Inovio Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human papillomavirus protein E6 (HPV E6) | Target Info | Modulator | [4] |
| Human papillomavirus protein E7 (HPV E7) | Target Info | Modulator | [4] | |
| Pathway Interaction Database | Regulation of Telomerase | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01304524) A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3. U.S. National Institutes of Health. | |||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.